A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.
Trial Details
NCT Number NCT07728383
Lead Sponsor Gila Therapeutics, Inc.
Conditions
(from sponsor)		 Obesity & Overweight
Related terms Obesity, Overweight
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov